Intact Investment Management Inc. bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,400 shares of the pharmaceutical company’s stock, valued at approximately $213,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. BlackRock Inc. grew its holdings in Vertex Pharmaceuticals by 0.8% during the 2nd quarter. BlackRock Inc. now owns 19,405,981 shares of the pharmaceutical company’s stock worth $2,500,849,000 after acquiring an additional 159,601 shares during the last quarter. Vanguard Group Inc. grew its holdings in Vertex Pharmaceuticals by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock worth $2,188,196,000 after acquiring an additional 504,982 shares during the last quarter. Jennison Associates LLC grew its holdings in Vertex Pharmaceuticals by 253.8% during the 2nd quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock worth $651,454,000 after acquiring an additional 3,626,368 shares during the last quarter. TIAA CREF Investment Management LLC grew its holdings in Vertex Pharmaceuticals by 28.1% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 2,077,303 shares of the pharmaceutical company’s stock worth $267,702,000 after acquiring an additional 456,290 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Vertex Pharmaceuticals by 4.5% during the 2nd quarter. Wells Fargo & Company MN now owns 1,916,227 shares of the pharmaceutical company’s stock worth $246,944,000 after acquiring an additional 83,314 shares during the last quarter. 93.36% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have weighed in on VRTX shares. Janney Montgomery Scott raised shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $98.00 target price on the stock in a report on Wednesday, July 19th. Stifel Nicolaus upped their price objective on shares of Vertex Pharmaceuticals from $130.00 to $154.00 and gave the company a “buy” rating in a research note on Tuesday, July 18th. Jefferies Group LLC initiated coverage on shares of Vertex Pharmaceuticals in a research note on Monday, July 10th. They issued a “buy” rating and a $155.00 price objective on the stock. Maxim Group set a $195.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 19th. Finally, J P Morgan Chase & Co set a $175.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have issued a buy rating to the company’s stock. Vertex Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $173.15.

ILLEGAL ACTIVITY WARNING: “Intact Investment Management Inc. Takes $213,000 Position in Vertex Pharmaceuticals Incorporated (VRTX)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/intact-investment-management-inc-takes-213000-position-in-vertex-pharmaceuticals-incorporated-vrtx/1675606.html.

In related news, EVP Stuart A. Arbuckle sold 6,290 shares of Vertex Pharmaceuticals stock in a transaction on Friday, October 27th. The shares were sold at an average price of $143.97, for a total value of $905,571.30. Following the sale, the executive vice president now owns 116,952 shares in the company, valued at $16,837,579.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Ian F. Smith sold 4,250 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $155.39, for a total transaction of $660,407.50. Following the sale, the chief financial officer now owns 120,138 shares in the company, valued at approximately $18,668,243.82. The disclosure for this sale can be found here. In the last quarter, insiders sold 198,030 shares of company stock worth $28,878,352. 1.80% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million for the quarter, compared to analysts’ expectations of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The firm’s revenue for the quarter was up 39.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.16 earnings per share.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.